$RGEN SEC Filings

Repligen Corporation41 Seyon StreetBuilding #1, Suite 100Waltham, Massachusetts 02453

Received 700 shares as a grant or award · Granted 675 Stock Option (Right to Buy)

Sold 5,535 shares ($1.04M) · Received 4,202 shares by exercise or conversion ($651K)

WALTHAM, MA - October 6, 2026 – Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company focused on bioprocessing technology leadership, today announced it has completed the previously announced acquisit...

Gave up 1,248 shares to cover exercise price or tax ($227K)

Gave up 421 shares to cover exercise price or tax ($79.9K)

Received 12,946 shares by exercise or conversion ($2.01M) · Sold 12,946 shares ($2.46M)

Received 5,426 shares by exercise or conversion ($769K) · Sold 5,426 shares ($977K)

On September 10, 2026, Karen A. Dawes notified Repligen Corporation (“Repligen”) that she will be retiring from the Repligen Board of Directors (the “Board”) after over twenty years of distinguished service to Repligen, effective as of S...

Gave up 2,842 shares to cover exercise price or tax ($482K) · Sold 3,035 shares ($504K)

As previously disclosed, on July 21, 2026, Repligen Corporation, a Delaware corporation (“Repligen”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Bravo Merger Sub I, Inc., a Delaware corporation and wholly ...